Movement Activities in Patients with Inherited Polyneuropathy

Czech version

Authors: A. Kobesová ¹; R. Mazanec ²
Authors‘ workplace: Klinika rehabilitace 2. LF UK a FN V Motole, Praha ¹; Neurologická klinika dospělých 2. LF UK a FN v Motole, Praha ²
Published in: Cesk Slov Neurol N 2008; 71/104(3): 277-284
Category: Review Article

Overview

Inherited polyneuropathy is currently an incurable disease with progressive symptoms affecting young individuals. Complex case management must include education and instruction in appropriate movement and sporting activities. Moderate strengthening exercises have not been found to be harmful and may reduce the progression of muscle paresis while increasing strength and improve the performance of activities of daily living. Customized exercise plans must be regularly rechecked and updated in order to avoid overuse weakness, pain and extreme post-exercise fatigue. The current literature suggests that exercise may be more beneficial if creatine monohydrate peroral supplementation is added to the diet. Current clinical management requires the application of appropriate movement activities for every individual with inherited polyneuropathy, even those whose conditions have progressed to present with extreme disabilities.

Key words:
inherited polyneuropathy – strengthening exercises – sport – creatin monohydrate

Sources

1. Dyck PJ, Chance P, Lebo R. Hereditary motor and sensory neuropathies. In: Dyck PJ, Thomas PK, Griffin JW (Eds). Peripheral Neuropathy. 3rd ed. Philadelphia: W.B. Saunders Company 1993: 1094–1136.

2. Smith AG. Charcot-Marie-tooth disease. Arch Neurol 2001; 58(6): 1014–1016.

3. Shy ME. Charcot-Marie-Tooth disease: an update. Curr Opin Neurol 2004; 17(5): 579–585.

4. Züchner S, Vance JM. Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat Clin Pract Neurol 2006; 2(1): 45–53.

5. Haberlová J, Mazanec R, Seeman P. Dědičné periferní neuropatie. Neurol pro Praxi 2006; 3: 147–152.

6. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980; 103(2): 259–280.

7. Vinci P. Rehabilitation management of Charcot-Marie-Tooth disease. Italy: Spazio Immagine Editore 2001.

8. Kobesová A, Horáček O. Možnosti rehabilitace u pacientů s chorobou Charcot-Marie-Tooth. Rehab Fyz Lék 2002; 9(1): 23–30.

9. Kobesová A, Smetana P, Suzan J, Smetana V, Baránková L, Horáček O. Zásady protetické péče u pacientů s hereditární motoricko-senzorickou neuropatií (HMSN). Rehab Fyz Lék 2004; 11(4): 169–175.

10. Horacek O, Mazanec R, Morris CE, Kobesova A. Spinal deformities in hereditary motor and sensory neuropathy: a retrospective qualitative, quantitative, genotypical, and familial analysis of 175 patients. Spine 2007; 32(22): 2502–2508.

11. Horáček O, Mazanec R, Kobesová A, Seeman P. Deformity páteře u hereditární motoricko-senzitivní neuropatie. Cesk Slov Neurol N 2005; 68/101(2): 109–115.

12. Vinci P, Villa LM, Castagnoli L, Marconi C, Lattanzi A, Manini MP et al. Handgrip impairment in Charcot-Marie-Tooth disease. Eura Medicophys 2005; 41(2): 131–134.

13. Vinci P, Esposito C, Perelli SL, Antenor JA, Thomas FP. Overwork weakness in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil 2003; 84(6): 825–827.

14. Quintart C, Baillon JM, Libotte M. Pathologic fracture of the tibia associated with Charcot-Marie-Tooth Disease. Acta Orthop Belg 1999; 65(1):105–108.

15. Lindeman E, Spaans F, Reulen J, Leffers P, Drukker J. Progressive resistance training in neuromuscular patients. Effects on force and surface EMG. J Electromyogr Kinesiol 1999; 9(6): 379–384.

16. Vinci P. Strengthening of the proximal muscles in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil 2001; 82(4): 563.

17. Milner-Brown HS, Miller RG. Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil 1988; 69(1): 4–9.

18. Kilmer DD. The role of exercise in neuromuscular disease. Phys Med Rehabil Clin N Am 1998; 9(1): 115–125.

19. Clarkson PM. Exercise-induced muscle damage-animal and human models. Med Sci Sports Exerc 1992; 24(5): 510–511.

20. Clarkson PM, Sayers SP. Etiology of exercise-induced muscle damage. Can J Appl Physiol 1999; 24(3): 234–248.

21. McNeil PL, Ito S. Molecular traffic through plasma membrane disruptions of cells in vivo. J Cell Sci 1990; 96(Pt 3): 549–556.

22. McNeil PL, Khakee R. Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am J Pathol 1992; 140(5): 1097–1109.

23. Carter GT, Abresch RT, Fowler WM jr. Adaptations to exercise training and contraction-induced muscle injury in animal models of muscular dystrophy. Am J Phys Med Rehabil 2002; 81(Suppl 11): S151–S161.

24. Chetlin RD, Gutmann L, Tarnopolsky M, Ullrich IH, Yeater RA. Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. Arch Phys Med Rehabil 2004; 85(8): 1217–1223.

25. Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM. Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1993; 74(7): 711–715.

26. Kilmer DD. Response to resistive strengthening exercise training in humans with neuromuscular disease. Am J Phys Med Rehabil 2002; 81(Suppl 11): S121–S126.

27. Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle Nerve 2004; 30(1): 69–76.

28. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5(3): 347–350.

29. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998; 18(1): 156–163.

30. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52(4): 854–857.

31. Wyss M, Felber S, Skladal D, Koller A, Kremser C, Sperl W. The therapeutic potential of oral creatine supplementation in muscle disease. Med Hypotheses 1998; 51(4): 333–336.

32. Doherty TJ, Lougheed K, Markez J, Tarnopolsky MA. Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Neurology 2001; 57(3): 559–560.

33. Silbernagl S, Despopoulos A. Atlas fyziologie člověka. 6th ed. Praha: Grada 2004.

34. Taaffe DR, Pruitt L, Pyka G, Guido D, Marcus R. Comparative effects of high- and low-intensity resistance training on thigh muscle strength, fiber area, and tissue composition in elderly women. Clin Physiol 1996; 16(4): 381–392.

35. Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE. Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease. Muscle Nerve 2006; 34(5): 586–594.

36. Mulder T, den Otter R, van Engelen B. The regulation of fine movements in patients with Charcot Marie Tooth, type Ia: some ideas about continuous adaptation. Motor Control 2001; 5(2): 200–214.

37. Kilmer DD. The role of exercise in neuromuscular disease. Phys Med Rehabil Clin N Am 1998; 9(1): 115–125.

38. Lindeman E, Spaans F, Reulen J, Leffers P, Drukker J. Progressive resistance training in neuromuscular patients. Effects on force and surface EMG. J Electromyogr Kinesiol 1999; 9(6): 379–384.

39. McCrory MA, Kim HR, Wright NC, Lovelady CA, Aitkens S, Kilmer DD. Energy expenditure, physical activity, and body composition of ambulatory adults with hereditary neuromuscular disease. Am J Clin Nutr 1998; 67(6): 1162–1169.

40. Fowler WM Jr, Abresch RT, Koch TR, Brewer ML, Bowden RK, Wanlass RL. Employment profiles in neuromuscular diseases. Am J Phys Med Rehabil 1997; 76(1): 26–37.

41. Vignos PJ jr. Physical models of rehabilitation in neuromuscular disease. Muscle Nerve 1983; 6(5): 323–338.

42 Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM. Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1993; 74(7): 711–715.

43. Van Engelen BG, Kalkman JS, Schillings ML, Van Der Werf SP, Bleijenberg G, Zwarts MJ. Fatigue in neuromuscular disease. Ned Tijdschr Geneeskd 2004; 148(27): 1336–1341.

44. Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet 2004; 363(9413): 978–988.

45. Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9(6): 456–460.

46. Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev 2001; 81(4): 1725–1789.

47. Schillings ML, Hoefsloot W, Stegeman DF, Zwarts MJ. Relative contributions of central and peripheral factors to fatigue during a maximal sustained effort. Eur J Appl Physiol 2003; 90(5–6): 562–568.

48. Di Lazzaro V, Oliviero A, Tonali PA, Felicetti L, De Marco MB, Saturno E et al. Changes in motor cortex excitability in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2004; 14(1): 39–45.

49. Liepert J, Schoser BG, Weiller C. Motor excitability in myopathy. Clin Neurophysiol 2004; 115(1): 85–89.

50. Oliveri M, Brighina F, La Bua V, Aloisio A, Buffa D, Fierro B. Magnetic stimulation study in patients with myotonic dystrophy. Electroencephalogr Clin Neurophysiol 1997; 105(4): 297–301.

51. Lee MJ, Nelson I, Houlden H, Sweeney MG, Hilton-Jones D, Blake J et al. Six novel connexin32 (GJB1) mutations in X-linked Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry 2002; 73(3): 304–306.

52. Shield A, Zhou S. Assessing voluntary muscle activation with the twitch interpolation technique. Sports Med 2004; 34(4): 253–267.

53. Lindeman E, Spaans F, Reulen J, Leffers P, Drukker J. Progressive resistance training in neuromuscular patients. Effects on force and surface EMG. J Electromyogr Kinesiol 1999; 9(6): 379–384.

54. Fowler WM jr. Role of physical activity and exercise training in neuromuscular diseases. Am J Phys Med Rehabil 2002; 81(Suppl 11): S187–S195.

55. Sampson R. CMT and Exercise. Lindacrabtree [online]. 2006. Dostupné z: <http://www.lindacrabtree.com/cmtnews/Exercise/Sampson%20questionnaire.htm>.

56.Crabtree L, Carter G. Exercise, weight loss and CMT. Lindacrabtree [online]. 2006. Dostupné z: <http://www.lindacrabtree.com/cmtnews/Exercise/Dr.%20Carter%20interview.html>.

57. Rugo PE. Charcot-Marie-Tooth Disease and Exercise. Lindacrabtree [online]. 2006. Dostupné z: <http://www.lindacrabtree.com/cmtnews/Exercise/Exercise%20Methods.htm>.

58. Kobesová A, Horáček O, Mazanec R, Smetana P, Truc M, Bojar M. Dědičné neuropatie – mezioborová diagnóza. Postgraduální medicína 2007; 9(2): 139–147.